Indian Diabetes Market to Reach INR 6300 Crore by 2015

A new report expects the Indian diabetes market to grow exponentially in the coming years.
A new report from IMARC Group entitled Indian Diabetes Market Report & Outlook for 2010-2015 expects the Indian diabetes market to grow at a CAGR of 22% during 2011-2015 reaching revenues worth INR 6300 Crores. The report gives a comprehensive insight into the Indian diabetes market and serves as an excellent tool to understand not only the market trends, structure, drivers and restraints but also the outlook of the market till 2015. This report aims to serve as a statistical as well as an analytical guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into Indian diabetes market in some form or the other.

Report Highlights A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to INR 6300 Crores by 2015. In 2009, the market for Non-Insulin Anti-diabetics was worth INR 1377 Crores. This represented a highly fragmented market with USV being the leading player. USVs Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market. IMARC Group expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes. The Insulin Market was worth INR 527 Crores in 2009 with Abbott being the biggest player in this market. Sanofi Aventis Lantus (Insulin Glargine) represents one of the fastest growing drugs in the last five years. The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from the urban regions.

Forecasts: The report provides forecasts on: Number of diabetes patients Diagnosis and treatment rates in India Diabetes market Non-Insulin Anti-diabetics market Glitazones Biguanides Sulphonylureas Alpha-Glycosidase Inhibitors DPP-IV Inhibhitors GLP-1 Agonists Glinides All other Non-Insulin Anti-diabetic classes Insulin market Competitive Landscape: This section covers: 2005-2009 sales and market shares of top players in the diabetes market 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market 2005-2009 sales and market shares of top players in various Non-Insulin drug classes

2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin drug classes 2005-2009 sales and market shares of top players in the Insulin market 2005-2009 sales of top drugs comprising the portfolio of key players in the Insulin market.

Key Questions Answered in this report What is the total size of the diabetes population in India and what are its characteristics? What are the diagnosis and drug treatment rates for diabetes in India? What are the key factors driving the growth of diabetes medication in India? What is the size and breakup of the total diabetes market in India? What is the size and breakup of the total Non-Insulin diabetes market in India? What is the size and breakup of the total Insulin market in India? Who are the key players in the Indian diabetes market and how have they performed? What is the outlook of the Indian diabetes market in the next five years? Which new products are expected to be launched in the next five years? Which therapy classes will show the highest growth in the next five years? What are the road blocks in the Indian diabetes market?

Table of Contents
1. 2. EXECUTIVE SUMMARY DIABETES DISEASE OVERVIEW 2.1 WHAT IS DIABETES? 2.2 DIABETES DIAGNOSIS AND TREATMENT 2.2.1 Diagnosis 2.2.2 Treatment 2.3 DIABETES COMPLICATIONS 3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA 3.1 3.2 3.3 3.4 3.5 4. INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD. INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY IMPROVING DIAGNOSIS AND TREATMENT RATES LARGE UNTAPPED MARKET BRIGHT OUTLOOK FOR INNOVATIVE DRUGS

THE INDIAN DIABETES EPIDEMIOLOGY 4.1 TOTAL PREVALENCE 4.1.1 Type1 & Type2 Prevalence 4.1.2 Urban and Rural Prevalence 4.1.3 Prevalence of Diabetes by Sex 4.1.4 Prevalence of Diabetes by Age Group 4.1.5 Prevalence of Diabetes in Various Regions in India 4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA

5.

THE INDIAN DIABETES MARKET 5.1 5.2 5.3 MARKET TREND (2005-2009) MARKET SEGMENTATION (2005-2009) MARKET FORECASTS (2010-2015)

6.

THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET 6.1 6.2 6.3 MARKET TREND (2005-2009) COMPETITIVE LANDSCAPE (2005-2009) MARKET FORECASTS (2010-2015)

6.4 MARKET SEGMENTATION (2005-2015) 6.4.1 Glitazones 6.4.1.1 Market Trend (2005-2009) 6.4.1.2 Competitive Landscape 6.4.1.3 Market Forecasts (2010-2015) 6.4.2 Biguanides 6.4.2.1 Market Trend (2005-2009) 6.4.2.2 Competitive Landscape 6.4.2.3 Market Forecasts (2010-2015) 6.4.3 Sulphonylureas 6.4.3.1 Market Trend (2005-2009) 6.4.3.2 Competitive Landscape 6.4.3.3 Market Forecasts (2010-2015) 6.4.4 Alpha-Glycosidase Inhibitors 6.4.4.1 Market Trend (2005-2009) 6.4.4.2 Competitive Landscape 6.4.4.3 Market Forecasts (2010-2015) 6.4.5 Dpp-IV Inhibitors 6.4.5.1 Market Trend (2008-2009) 6.4.5.2 Competitive Landscape 6.4.5.3 Market Forecasts (2010-2015) 6.4.6 Glinides 6.4.6.1 Market Trend (2005-2009) 6.4.6.2 Competitive Landscape 6.4.6.3 Market Forecasts (2010-2015) 6.4.7 Glp-1 Agonists 6.4.7.1 Market Trend (2008-2009) 6.4.7.2 Competitive Landscape 6.4.7.3 Market Forecasts (2010-2015) 6.4.8 All other Classes 6.4.8.1 Market Trend (2005-2009) 6.4.8.2 Competitive Landscape 6.4.8.3 Market Forecasts (2010-2015) 7. THE INDIAN INSULIN MARKET 7.1 MARKET TREND (2005-2009) 7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009) MARKET SEGMENTATION BY MODE OF ACTION 7.3 COMPETITIVE LANDSCAPE 7.3.1 Share of key Players 7.3.2 Portfolio of Key Players 7.4 MARKET FORECASTS (2010-2015) 8. ROAD BLOCKS 8.1 8.2 8.3 8.4 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES HIGHLY FRAGMENTED AND GENERICIZED MARKET LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia

Email: apac@imarcgroup.com Phone: +91-120-425-6531 IMARC Group North America Email: america@imarcgroup.com Phone: +1-631-791-1145 IMARC Group Europe, Middle East & Africa Email:ema@imarcgroup.com Phone: +44-702-409-7331 To know more please visit: http://www.imarcgroup.com/global-healthcare-cold-chain-logisticsmarket-report-forecast-2011-2016/
Keywords: Indian antibodies market, Indian diagnostic market, Indian immunodiagnostics market, Indian immunology market, Indian monoclonal antibodies market, Indian biosimilar market,